Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.785 SEK 0.74% Market Closed
Market Cap: 555.2m SEK

Net Margin
Ascelia Pharma AB

0%
Current
0%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-85.1m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
Ascelia Pharma AB
STO:ACE
555.2m SEK N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
129.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Ascelia Pharma AB
Glance View

Market Cap
555.2m SEK
Industry
Biotechnology

Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.

ACE Intrinsic Value
33.399 SEK
Undervaluation 86%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-85.1m
/
Revenue
0
What is the Net Margin of Ascelia Pharma AB?

Based on Ascelia Pharma AB's most recent financial statements, the company has Net Margin of 0%.

Back to Top